Top

Strahlentherapie und Onkologie

Published in:

01-06-2020 | Literatur kommentiert

Verminderung des Risikos eines In-Brust-Rezidivs: externe akzelerierte Teilbrust- vs. Ganzbrustradiotherapie für brusterhaltend operierte Patientinnen mit DCIS oder nodal-negativem Mammakarzinom

Die multizentrische, randomisierte RAPID-Studie

Author: Prof. Dr. med. Rainer Souchon

Published in: Strahlentherapie und Onkologie | Issue 6/2020

Auszug

Nach brusterhaltender Operation vermindert eine perkutane Radiotherapie der gesamten Brust (WBI) mit werktäglich einmaligen Behandlungen über 3–5 Wochen die Lokalrezidivraten und führt zu guten kosmetischen Ergebnissen. Akzelerierte Teilbrustbestrahlungen (APBI) des Tumorbetts, appliziert innerhalb von einer Woche, sollten die Behandlungen komfortabler machen. Im RAPID-Trial wurde untersucht, ob eine External-beam-APBI (EB-APBI) einer WBI nicht möglicherweise unterlegen ist. …

Krug D, Baumann R, Budach W et al (2017) Breast cancer expert panel of the German Society of Radiation Oncology (DEGRO). Current controversies in radiotherapy for breast cancer. Radiat Oncol 12(1):25. https://doi.org/10.1186/s13014-017-0766-3 (Review)CrossRefPubMedPubMedCentral

Livi L, Meattini I, Marrazzo L et al (2015) Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5‑year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 51(4):451–463CrossRef

Rodriguez N, Sanz X, Dengra J et al (2013) Five-year outcomes, cosmesis, and toxicity with 3‑dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 87(5):1051–1057CrossRef

Smith BD, Arthur DW, Buchholz TA et al (2009) Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 74(4):987–1001. https://doi.org/10.1016/j.ijrobp.2009.02.031 CrossRefPubMed

Strnad V, Major T, Polgar C, Lotter M et al (2018) ESTRO-ACROP guideline: Interstitial multi-catheter breast brachytherapy as Accelerated Partial Breast Irradiation alone or as boost—GEC-ESTRO Breast Cancer Working Group practical recommendations. Radiother Oncol 128(3):411–420. https://doi.org/10.1016/j.radonc.2018.04.009 CrossRefPubMed

Strnad V, Krug D, Sedlmayer F et al (2020) DEGRO practical guideline for partial-breast irradiation. Strahlenther Onkol. https://doi.org/10.1007/s00066-020-01613-z CrossRefPubMed

Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO), Duma MN, Baumann R, Budach W et al (2019) Heart-sparing radiotherapy techniques in breast cancer patients: a recommendation of the breast cancer expert panel of the German society of radiation oncology (DEGRO). Strahlenther Onkol 195(10):861–871. https://doi.org/10.1007/s00066-019-01495-w CrossRef

Piroth MD, Baumann R, Budach W et al (2019) Heart toxicity from breast cancer radiotherapy : Current findings, assessment, and prevention. Strahlenther Onkol 195(1):1–12. https://doi.org/10.1007/s00066-018-1378-z (Review)CrossRefPubMed

RAPID trial investigators, Peterson D, Truong PT, Parpia S et al (2015) Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. Int J Radiat Oncol Biol Phys 91(5):968–976. https://doi.org/10.1016/j.ijrobp.2014.12.040 CrossRef

10.

RAPID Trial Investigators, Whelan TJ, Julian JA, Berrang TS et al (2019) External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet 394:2165–2172. https://doi.org/10.1016/S0140-6736(19)32515-2 CrossRef

11.

Coles CE, Griffin CL, Kirby AM et al (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5‑year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390(10099):1048–1060CrossRef

12.

Vicini FA, Cecchini RS, White JR et al (2019) Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 394(10215):2155–2164. https://doi.org/10.1016/S0140-6736(19)32514-0 CrossRefPubMed

Title: Verminderung des Risikos eines In-Brust-Rezidivs: externe akzelerierte Teilbrust- vs. Ganzbrustradiotherapie für brusterhaltend operierte Patientinnen mit DCIS oder nodal-negativem Mammakarzinom
Die multizentrische, randomisierte RAPID-Studie
Author: Prof. Dr. med. Rainer Souchon
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 6/2020
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-020-01609-9

At a glance: The STEP trials

Springer Medicine

Verminderung des Risikos eines In-Brust-Rezidivs: externe akzelerierte Teilbrust- vs. Ganzbrustradiotherapie für brusterhaltend operierte Patientinnen mit DCIS oder nodal-negativem Mammakarzinom

Die multizentrische, randomisierte RAPID-Studie

Auszug

At a glance: The STEP trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 6/2020

Risk stratification of pulmonary toxicities in the combination of whole lung irradiation and high-dose chemotherapy for Ewing sarcoma patients with lung metastases: a review

Model-based calculation of thyroid gland normal tissue complication probability in head and neck cancer patients after radiation therapy

Prognostic value of a 15-gene hypoxia classifier in oropharyngeal cancer treated with accelerated chemoradiotherapy

Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters

Age-dependent hemato- and nephrotoxicity in patients with head and neck cancer receiving chemoradiotherapy with weekly cisplatin

Organerhaltende Therapie des Harnblasenkarzinoms